
Akeso Biopharma trades up after $333m Hong Kong IPO

Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.
The company’s shares opened at HK$23.80 and soon rose as high at HK$24.25 before settling back to HK$23.80 towards the end of morning trading on April 24. Akeso sold approximately 149.5 million shares...
Latest News
Mitsui, Nomura acquire real assets manager New Forests
Japan’s Mitsui & Co. and Nomura Holdings have agreed to acquire 100% of New Forests, an Australia-headquartered sustainable real assets investment manager focused on forestry, land management, and conservation.
Thai food supply chain player secures $23.5m Series B
Openspace Ventures has participated in a USD 23.5m Series B funding round for Freshket, a Thailand-based farm-to-table agricultural supply chain start-up.
Philippines fintech player Coins raises $30m
Coins, a Philippines-based financial technology provider focused on blockchain-enabled payment services, has received a USD 30m investment led by Ribbit Captial.
Coatue, Insight lead Series D for Indonesia's Xendit
Coatue Management and Insight Partners have led a USD 300m Series D round for Indonesian payments infrastructure platform Xendit.